Given that Tamoxifen is already a highly promising drug in the treatment of hormone receptor positive breast cancer, further development of Tamoxifen derived tumor-specific boron moieties may offer potential for highly effective, low toxicity BNCT treatments in breast cancer. Here, NR4A1 is linked to breast carcinoma.